Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06880055 · ClinicalTrials.gov registry record
Shield Post-Approval Study Protocol
A clinical trial of Colorectal Cancer, sponsored by Guardant Health.
- Recruiting
- Registry status
- 3,375
- Enrollment target
- 20
- Study locations
NCT06880055: Recruiting study of Colorectal Cancer, sponsored by Guardant Health.
NCT06880055 is a study of Colorectal Cancer that is actively recruiting participants, run by Guardant Health. The registered enrollment target is 3,375 participants, above the 1,536-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06880055, a study of Colorectal Cancer, is actively recruiting participants, sponsored by Guardant Health.
- RECRUITING
- Registry status
- 3,375 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.
Primary Outcome
* Advanced Neoplasia Specificity * AA Sensitivity * CRC Sensitivity * PPV for: CRC, AA, and advanced neoplasia. * NPV for: CRC and advanced neoplasia
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Shield Blood Test for colo-rectal cancer Screening
Study Locations (20)
Illinois
- Digestive Disease Consultants - Bourbonnais
- Digestive Disease Consultants - Bourbonnais
- Christie Clinic - Champaign
- Christie Clinic - Champaign
- GI Solutions of Illinois - Chicago
- GI Solutions of Illinois - Chicago
- Digestive Health Services - Downers Grove
- Digestive Health Services - Downers Grove
- Gastroenterology and Internal Medicine Specialists (GAIMS) - Lake Barrington
- Gastroenterology and Internal Medicine Specialists (GAIMS) - Lake Barrington
California
- Alliance Research Institute, LLC - Canoga Park
- Paragon Rx Clinical, Inc. - Garden Grove
- Amicis Research Center - Granada Hills
- Desert Oasis Healthcare Medical Group - Palm Springs
Arizona
- Southeast Valley Gastroenterology Consultants - Chandler
- Southeast Valley Gastroenterology Consultants - Gilbert
Connecticut
- Digestive Disease Associates - Branford
- Digestive Disease Associates - Branford
Florida
- Gastroenterology Consultants of Boca Raton, LLC - Boca Raton
- Physicians Group of South Florida - North Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,375 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2030-12-01 |
What NCT06880055 shows while recruiting
NCT06880055 is an observational study that tracks outcomes without assigning an intervention. Its 3,375 participants enrollment target places it among the larger protocols in the corpus, above the 1,536-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (120% higher).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Shield Blood Test for colo-rectal cancer Screening is the first listed.
NCT06880055 names 20 study sites across 5 states, led by Illinois, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06880055 about?
NCT06880055 is a clinical study titled "Shield Post-Approval Study Protocol". The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi...
What is the current status of trial NCT06880055?
This trial is currently recruiting. The enrollment target is 3,375 participants. The study started on 2025-07-14. Estimated completion is 2030-12-01.
What conditions does trial NCT06880055 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT06880055?
The interventions under investigation include: Shield Blood Test for colo-rectal cancer Screening (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06880055?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06880055 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06880055's enrollment target sits among peer trials
3,375 22nd of 381 higher than 360 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI